×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Myeloma

Featured Content
Dr Noopur Raje opens this program with a brief discussion on the basics of multiple myeloma. She describes what the disease is, highlights key risk factors, and explains how she helps educate her patients on their diagnosis. Cynthia Harrington discusses her role as a nurse practitioner when working with multiple myeloma patients and why a team-based approach between healthcare providers and the patient is important.
Richard E. Farmer
Conor Killmurray
The Food and Drug Administration approved the targeted therapy Sarclisa for the treatment of patients with multiple myeloma. Here’s what you need to know.
 
Katie Kosko
Terry White, who has lived with multiple myeloma for more than a decade, offers reassurance to other patients.
 
Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with the co-chair of the MMRF’s Laugh for Life event, as well as this year’s “Spirit of Hope” award recipient.
 
Beth Fand Incollingo
The Food and Drug Administration approved Sarclisa, as adding the targeted drug to combination therapy delays the progression of multiple myeloma in previously treated patients.
 
Kristie L. Kahl and Lee Greenberger
Lee Greenberger, chief scientific officer at the Leukemia and Lymphoma Society, discusses treatment advances in the multiple myeloma space.
Sponsored Content
Patient Rod Gilmore shares his experience with multiple myeloma and the importance of creating a strategy to manage the disease.
Kristie L. Kahl
The Food and Drug Administration granted a priority review to belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma.
Conor Killmurray
A multiple myeloma expert helps newly diagnosed patients understand the standard of care for their disease.
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×